Fundraising Fox

Dimension Capital

Venture capitalActively deploying

San Francisco · Seed–Late Stage · 14 people tracked

Also known as DIMENSION CAPITAL MANAGEMENT LLC · DIMENSION MANAGEMENT, L.P.

Fox Verdict
Sign up to see your fit

Investment thesis

Dimension positions itself as a multistage, research-oriented investment firm focused on companies operating at the frontiers of science and computing. It emphasizes a research-driven approach, backing ventures that combine advances in the life sciences and computational fields.

Source: firm website, verified Aug 25, 2026.

Stage
Seed–Late Stage
Check
$1M – $10M
HQ
San Francisco, New York, US
Leads rounds
Leads
Instruments
Equity
Founded
2022
Last 12 months
2 investments
AUM
$7.3B
VC funds
2
Tracked investments
28

Team · 14 people

from the firm's website & curated & public directories

What they invest in

from 20 of 28 portfolio companies

AI & Machine Learning ×16Biotech ×15Deep Tech ×6Healthtech ×6SaaS ×5Enterprise Software ×4Developer Tools ×3Digital Health ×3

HQs:United States×18Canada×1Germany×1United Kingdom×1

Investments · 28 tracked

founders shown can be your intro path

By year:2025 · 42023 · 12022 · 22021 · 12019 · 22017 · 12016 · 12015 · 214 dated

Eikon TherapeuticsinNASDAQ: EIKNJan 2022SEC filingmedium confidence

BiotechHayward, US

Roger M. Perlmutter(Executive Officer, Director)

BoardJoshua Wolfe(Director)inDror Berman(Director)James Tananbaum(Director)Leon Chen(Director)

Board seatAdam Goulburn· per SEC Form D · $525M raise · filed Jan 2022

Co-investorsForesite CapitalLux Capital

Monte Rosa Therapeuticsmonterosatx.comin𝕏NASDAQ: GLUE

Monte Rosa develops molecular glue degrader (MGD) therapeutics using MGD chemistry, artificial intelligence, structural biology, and proteomics to target previously undruggable or inadequately drugged disease targets.

AI & Machine LearningBiotechDeep TechHealthtechBoston, US

Markus Warmuth(M.D., Chief Executive Officer)inSharon Townson(Ph.D., Chief Scientific Officer)John Castle(Ph.D., Chief Data and Information Officer)Filip Janku(M.D., Ph.D., Chief Medical Officer)Phil Nickson(Ph.D., J.D., Chief Business and Legal Officer)Magnus Walter(DPhil, Chief Technology Officer)

Co-investorsAisling CapitalNew Enterprise Associates (NEA)Versant VenturesHBM PartnersAmzak HealthAvoro Capital Advisors+1 more

3Scan3scan.comJun 2016SEC filingmedium confidence

San Francisco, US

Todd Huffman(Executive Officer, Director)Megan Klimen(Executive Officer)Adam Goulborn(Director)

BoardJoshua Wolfe(Director)Matt Ocko(Director)

Board seatAdam Goulburn· per SEC Form D · $14M raise · filed Jul 2016

Co-investorsComet Labs

Authoreaauthorea.comDec 2015AcquiredSEC filingmedium confidence

Collaborative scholarly writing tool turned preprint archive, owned by Wiley since 2018.

New York, US

Nathan Jenkins(Executive Officer)Alberto Pepe(Executive Officer, Director)Matteo Cantiello(Director)Brian Cohen(Director)John F Frankel(Director)

Board seatAdam Goulburn· per SEC Form D · $1.5M raise · filed Jan 2016

Co-investorsFf Venture CapitalNew York Venture PartnersBloomberg Beta

CareGuardianDec 2015SEC filingmedium confidence

New York, US

Joshua Bruno(Executive Officer, Director)

BoardBrad Gillespie(Director)Ann Lamont(Director)

Board seatAdam Goulburn· per SEC Form D · $30.3M raise · filed Jan 2016

Drone Racing Leaguethedroneracingleague.comJun 2019AcquiredSEC filingmedium confidence

Professional drone racing league whose pilots fly identical custom-built FPV drones on 3D courses broadcast worldwide.

New York, US

Nicholas Horbaczewski(Executive Officer, Director)

Board seatAdam Goulburn· per SEC Form D · $50M raise · filed Jun 2019

Co-investorsCerity Partners VenturesChaifetz GroupLux CapitalRSE VenturesCRCM VenturesHearst Ventures

Enveda Therapeutics, Inc.Mar 2023SEC filingmedium confidence

Boulder, US

Board seatZavain Dar· per SEC Form D · $62.5M raise · filed Mar 2023

Hometeam Technologies, Inc.Jun 2022SEC filingmedium confidence

New York, US

Board seatAdam Goulburn· per SEC Form D · $15.1M raise · filed Jun 2022

NewLimitnewlimit.com𝕏May 2025

NewLimit develops epigenetic reprogramming medicines to extend healthspan and treat age-related diseases at the intersection of computer science and biotechnology.

AI & Machine LearningBiotechLongevitySouth San Francisco, US

Brian Armstrong(Co-founder, Board of Directors)inBlake Byers(Director)inJacob Kimmel(Director)inMichael Polansky(Executive Officer)

Board seatZavain Dar· per SEC Form D

Co-investorsS32Valor Equity Partners8VCAbstract Venturesage1Beyond Capital+6 more

Odyssey Therapeuticsodysseytx.comin𝕏Dec 2025

Odyssey Therapeutics develops small molecule and protein therapeutics targeting upstream signaling nodes and innate immune system mechanisms to prevent pathological inflammation.

BiotechMedical DevicesCambridge, US

Gary D Glick(Executive Officer, Director)in

BoardJill Carroll(Director)inCarl Gordon(Director)inValerie Odegard(Director)Jeffrey Leiden(Director)Charles Baum(Director)

Board seatNan Li· per SEC Form D

Co-investorsActivant CapitalBalderton CapitalCatalio Capital Management, LPForesite CapitalGlobal BioAccess FundGreatPoint Ventures+6 more

Pagerpager.cominJun 2021SEC filingmedium confidence

Pager Health provides a white-label care navigation platform that combines AI with clinicians to help members find, access, and stay engaged with healthcare.

AI & Machine LearningDigital HealthHealthtechNew York, US

Gaspard de Dreuzy(Executive Officer, Director)Phillip Eytan(Executive Officer, Director)Oscar Salazar(Director)Philip Eytan(Executive Officer, Director, Promoter)Walter Jin(Chairman & CEO)inSandy Clarke(Chief Financial Officer)in

Board seatAdam Goulburn· per SEC Form D · $50M raise · filed Jun 2021

Co-investorsHealth Catalyst CapitalNew Enterprise Associates (NEA)Streamlined VenturesMontage Ventures

Tempo Automationtempoautomation.comAug 2017SEC filingmedium confidence

San Francisco, US

Shashank Samala(Cofounder)Jeffrey McAlvay(Executive Officer, Director)Jesse Koenig(Executive Officer)

Board seatZavain Dar· per SEC Form D · $20.7M raise · filed Aug 2017

Co-investorsGrit VenturesKeiretsu ForumLux CapitalPoint72 VenturesSQN Venture Partners, LLCUncork Capital+1 more

Variant Biovariantbio.comin𝕏Sep 2019SEC filingmedium confidence

Variant Bio is a therapeutics company that uses human genomics to guide drug development, drawing on expertise across genetics, molecular biology, therapeutics, anthropology, and ethics.

AI & Machine LearningBiotechDigital HealthNew York, US

Kaja Wasik(Executive Officer, Director)Andrew Farnum(Chief Executive Officer)Stephane Castel(Co-Founder, Chief Scientific & Technology Officer)inCraig Basson(Chief Medical Officer, President of R&D)Holly Vance(Chief Operating Officer)

BoardJulie Sunderland(Director)

Board seatAdam Goulburn· per SEC Form D · $31.5M raise · filed Oct 2019

Co-investorsAlta PartnersGeneral CatalystLux CapitalSoftBank Vision Fund

Achiraachira.ai

Achira builds molecular world models that blend geometric deep learning, physics, and quantum chemistry to advance drug discovery and materials design.

AI & Machine LearningBiotechDeep Tech

John Chodera(President / CEO)inTheofanis Karaletsos

BoardZavain Dar(Board)in

Co-investorsCompoundNVIDIAAmplify PartnersDIMENSIONNVentures

AllStripesallstripes.comin𝕏acquired by PicnicHealth

AllStripes was a health technology company that built a research platform for rare diseases, collecting and de-identifying patients' medical records to power rare disease research.

Digital HealthHealthtech

Nancy Yu(Founder)in

Co-investorsGaruda VenturesJAZZ Venture PartnersLux CapitalMaveronShasta VenturesSpark Capital

Aspect Biosystemsaspectbiosystems.comin

Aspect Biosystems develops bioprinted tissue therapeutics using a platform that combines AI-powered bioprinting, computational design tools, therapeutic cells, and biomaterials to create implantable allogeneic tissues.

AI & Machine LearningBiotechLongevity

Tamer Mohamed(Founder & CEO)inSam Wadsworth(Co-founder & Chief Scientific Officer)inSimon Beyer(Co-founder & Chief Technology Officer)inLeela Paris(Chief Technical Operations Officer)inMike Scott(Chief Development Officer)inRay Smith(Chief Financial Officer)in

Co-investorsAngel ForumCivilization Ventures Management, LlcInBC Investment Corp.JDRF T1D FundPage One VenturesPallasite Ventures+4 more

Automataautomata.tech

Automata provides lab automation and data management tools, enabling researchers and technicians to generate accurate data at scale through intuitive workflow creation.

Advanced ManufacturingAI & Machine LearningDeep TechHardwareHealthtechLegalTechRoboticsSaaSLondon, GB

Mostafa ElSayed(CEO and Co-Founder)inSuryansh Chandra(Co-Founder)

Co-investorsAir Street CapitalBlue Wire CapitalEntrepreneur FirstHCVCHummingbird VenturesIn-Q-Tel+6 more

Axiom Bioaxi.omin

Axi.om uses agentic intelligence and AI to predict, explain, and fix drug toxicity early in development by leveraging the largest experimental-to-clinical dataset of profiled molecules linked to human clinical outcomes.

AI & Machine LearningBiotechMedical Devices

Co-investorsAbstract VenturesAmplify PartnersCRV (Charles River Ventures)Inception Studio CapitalAtria Ventures

Chai Discoverychaidiscovery.com

Chai Discovery builds a computer-aided design suite using artificial intelligence to design new molecules and drugs.

AI & Machine LearningBiotechDeep TechSan Francisco, US

Joshua Meier(Founder & CEO)inJack Dent(Founder)in

Co-investorsAmplify PartnersAvenir Growth CapitalBain Capital VenturesBattery VenturesDCVC (Data Collective)General Catalyst+12 more

Convokeconvoke.bioin𝕏

Convoke offers an AI platform that ingests and structures data from documents, scientific literature, SEC filings, and clinical data, and deploys custom agents to automate knowledge tasks and generate reports, manuscripts, and landscape analyses.

AI & Machine LearningBiotechEnterprise SoftwareHealthtechSaaS

Co-investorsAudaciousKleiner PerkinsACMEComma CapitalLux CapitalNot Boring Capital

Envedaenvedabio.com

Clinical-stage biotech using AI and metabolomics to decode natural chemistry and discover small-molecule medicines.

Viswa Colluru, PhD(Founder)in

Co-investorsAir Street CapitalCatalio Capital Management, LPFPVHummingbird VenturesJAZZ Venture PartnersKinnevik+6 more

Fiveonefourfiveonefour.comSep 2025 · $17M

Fiveonefour builds tooling focused on agent experience (AX), helping developers ship software that AI agents can use effectively.

AI & Machine LearningDeveloper ToolsSaaSPortland, US

Timote Gelinas Delisle(Executive Officer, Director, Promoter)Chris Crane(Founder)inNicolas Joseph(Founder)inChristopher M Crane(Director)

BoardNan Li(Director)

Co-investorsFlybridge Capital PartnersVermilion Cliffs VenturesRidge VenturesStage 2 Capital

Jamsocketmodal.comin𝕏Acquired

Modal provides a serverless cloud platform designed for data, AI, and machine learning applications, enabling developers to scale from zero to thousands of CPUs or GPUs with simple code.

AI & Machine LearningCloud ComputingDeveloper ToolsNew York, US

Erik BernhardssonAkshat Bubna(Founder)

Co-investorsAmplify PartnersLux CapitalRedpoint VenturesCreandumGeneral CatalystAbstraction Capital+8 more

Kaleidoscope Biokaleidoscope.bioin

Kaleidoscope provides a software platform for scientific R&D teams to track and communicate project data, manage complex research processes, and accelerate decision-making.

BiotechEnterprise SoftwareSaaSNew York City, US

Ewan Taylor(CSO and Co-founder)Geraldine Paulus(Co-founder, VP Operations)Brian Naughton(Co-founder and CTO)inDavid Yen(Founder)Bogdan Knezevic(Founder)in

Co-investorsAIN VenturesBurda Principal InvestmentsHAWKTAILHummingbird VenturesRally Ventures Management, Llc

Kimiakimiatx.com

Kimia develops a drug discovery platform called ATLAS that combines active learning, automated chemical synthesis, high-throughput screening, and machine learning to design and optimize novel drug molecules.

AI & Machine LearningBiotechDeep Tech

Stig Hansen(Founder)in

Co-investorsHorizons VenturesThe Column GroupAirTree VenturesBlackbird VenturesDIMENSIONSkip Capital

Laminlamin.aiin𝕏

Lamin provides a lineage-native lakehouse platform for biological R&D that enables scientists to query, trace, and validate complex biological datasets across academia, biotech, and pharma.

AI & Machine LearningBiotechData & InfrastructureDeveloper ToolsEnterprise SoftwareHealthtechMunich, DE

Alex Wolf(Co-Founder & CEO)inSunny Sun(Founder)inFrederic Enard(Co-CTO & Founding Engineer)

Co-investorsY Combinator

Stately Biostatelybio.comin

Stately Bio develops stem cell-derived regenerative and cell therapies using a machine learning platform that measures cell identity, behavior, and maturation directly from live-cell, label-free imaging.

AI & Machine LearningBiotechMedical Devices

Co-investorsAIX VenturesFoothill VenturesMitsui Global InvestmentAxial VCBoxOne VenturesCaffeinated Capital+1 more

Tamarind Biotamarind.bioin𝕏May 2025 · $13.6M

Tamarind provides a computational platform for protein and molecular engineering, offering AI and physics-based tools to design antibodies, peptides, enzymes, and small molecules.

AI & Machine LearningBiotechDeep TechEnterprise SoftwareSaaSSan Francisco, US

Deniz Kavi(Co-founder & CEO)inSherry Liu(Founder)in

Co-investorsTreeo VCY Combinator468 Capital

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.

Exits · 3

IPOs and acquisitions across the tracked portfolio

Eikon TherapeuticsNASDAQ: EIKNMonte Rosa TherapeuticsNASDAQ: GLUEAllStripesacq. by PicnicHealth

Portfolio news

latest coverage across their companies

Public market activity · per SEC filings

what is this? ⓘ

2 insider ownership filings (Forms 3/4/5)

at Odyssey Therapeutics, Inc. (ODTX)

From the firm's own SEC EDGAR filings — stakes and insider roles in public companies, typically portfolio companies after an IPO. Not a portfolio list published by the firm.

Frequently asked questions

What stage does Dimension Capital invest at?
Dimension Capital invests at the Seed, Series A, Series B, Series C, Growth, Late Stage stages.
What is Dimension Capital's typical check size?
Dimension Capital typically writes checks of $1M – $10M.
What sectors does Dimension Capital focus on?
Dimension Capital focuses on AI & Machine Learning, Biotech, Deep Tech, Healthtech, Medical Devices, SaaS.
Where is Dimension Capital located?
Dimension Capital is headquartered in San Francisco, US.
Does Dimension Capital lead rounds?
Yes, Dimension Capital leads investment rounds.

Media · Podcasts & interviews

featuring the team

Ventures #18 w/ Zavain Dar & Nan Li - Co-Founders & Managing Partners @ Dimension Capital | BIOS

BIOS · Nan Li

Images

Dimension Capital photo

Co-investors · 48

Lux Capital

Lux Capital is a venture capital firm that backs founders building transformative deep technologies, having been among the first investors in category-defining companies across AI, robotics, biotech, defense, and infrastructure.

$100K – $100M
Amplify Partners

Amplify Partners is a venture capital firm that backs technical founders — engineers, researchers, and scientists — building companies across AI/ML, data infrastructure, developer tools, and life sciences.

$500K – $5M
General Catalyst

General Catalyst is a venture capital firm operating as a partnership focused on company building and accelerating the growth of the businesses it backs.

$30M
New Enterprise Associates (NEA)

New Enterprise Associates (NEA) is a venture capital firm that invests in and provides long-term support to founders building new companies.

$200K – $40M
Menlo Ventures

Menlo Ventures is a venture capital firm that invests in transformative, early-stage AI companies across every layer of the modern AI stack, from applications and middleware to data infrastructure and foundation models.

$1M – $20M
GV (Google Ventures)

GV (Google Ventures) is a venture capital firm that has invested in artificial intelligence and machine learning since its early days, building a global portfolio of more than 100 AI companies across infrastructure, life sciences, and applications.

$250K – $50M
Uncork Capital

Uncork Capital (formerly SoftTech VC) is a seed-stage venture firm that invests early in founders, with a focus on AI-native companies building leverage and scale.

Both backed · 1
$3M – $5M
DCVC (Data Collective)

DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.

Both backed · 1
$5M – $25M
Spark Capital

Spark Capital is a venture capital firm that partners with founders, known for early investments including leading Twitter's Series B in 2008.

Both backed · 1
$500K – $25M
True Ventures

True Ventures is a venture capital firm established in 2005 that focuses on early-stage technology companies, with operations based in Silicon Valley.

Both backed · 1
$500K – $3M
Streamlined Ventures

Streamlined Ventures is an early-stage venture firm that partners with founders and invests at the seed stage to help build large-scale companies.

Both backed · 1
$100K – $1M
Maveron

Maveron is a venture capital firm that invests in entrepreneurs across web-enabled consumer services, education, and wellness sectors.

Both backed · 1
$100K – $8M
36 more co-investors

Point72 VenturesOrbiMedThe Column GroupPage One VenturesCompoundFPVKinnevikAndreessen HorowitzFelicis VenturesFoundation CapitalUnion Square Ventures (USV)Susa VenturesInnovation EndeavorsStellar CapitalAdditionTrajectory Ventures01 Advisors2048 VenturesFootworkBrainchild HoldingsPelion Venture PartnersDigital Currency GroupOyster VenturesHOF CapitalCrunchFundLombardstreet VenturesEuclid Venture PartnersBuilders VCPivotal Life SciencesAnkona Capital6 Dimensions CapitalBerkeley Blockchain XceleratorCatalio Capital ManagementAmplitude Venture CapitalInterlagosAvant Bio

Firms observed investing alongside Dimension Capital, from public investor directories. Shared companies are the overlap with Dimension Capital's recorded portfolio.

Similar investors

Featured in lists